The potential therapeutic approach of targeted inhibition of SMARCA2 has been put forth as a viable treatment strategy for cancers harboring SMARCA4 mutations, and proliferation of the SMARCA4 mutant xenograft model was effectively inhibited by allosteric inhibitors of SMARCA2/4 141. This evidence concerns the gene SMARCA2 and cancer.